Skip to main content
. 2018 Sep;7(Suppl 4):S462–S476. doi: 10.21037/tau.2018.06.09

Figure 8.

Figure 8

[18F]FDHT-PET images of a patient with biochemically recurrent metastatic prostate cancer (PSA =62 ng/mL) before (A) and after (B) initiation of flutamide demonstrate osseous and lymph node metastases (arrows) and subsequent treatment response. (Images courtesy of Farrokh Dehdashti, MD, Washington University in St. Louis).